<DOC>
	<DOC>NCT02168543</DOC>
	<brief_summary>- Locally delivered Alendronate (ALN) have potent inhibitory effect on bone and increases new bone formation in chronic periodontitis patients - Till date no study has reported the effect of local delivery of ALN in chronic periodontitis patients among smokers. Hence the aim of this study is to investigate the clinical and radiographic effects of locally delivered ALN as an adjunct to the non surgical treatment in smoker chronic periodontitis patients.</brief_summary>
	<brief_title>1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers</brief_title>
	<detailed_description />
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Systemically healthy subjects with probing depth (PD) ≥ 5 mm or periodontal attachment level (PAL) ≥ 4 to 6 mm and a radiographical vertical bone loss ≥ 3 mm No history of periodontal therapy in preceding last 6 months No use of antibiotics in the preceding 6 months Subjects with known systemic disease Known or suspected allergy to the ALN/bisphosphonate group Those on systemic ALN/bisphosphonate therapy Subjects with aggressive periodontitis, Use of smokeless tobacco in any form, Alcoholics Immunocompromised subjects Pregnant or lactating females</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>